Time‐release versus immediate‐release formulations of venlafaxine, paroxetine and bupropion: a comparative study of a nationally representative sample of the US working population. Issue 2 (12th February 2014)

• Record Type: Journal Article
• Authors: Al‐Ruthia, Yazed; Hong, Song Hee
• Is Part Of: Journal of pharmaceutical health services research. Volume 5:Issue 2(2014:Jun.)
• Page Start: 119
• Page End: 126
• Publication Date: 2014-02-12
• Subjects: Pharmacy -- Research -- Periodicals; Drugs -- Research -- Periodicals; Medical care -- Research -- Periodicals; Public health -- Research -- Periodicals; Pharmaceutical industry -- Periodicals; Health Services Research -- Periodicals; Economics, Pharmaceutical -- Periodicals; 615.1072
• DOI: 10.1111/jphs.12049
• Languages: English
• ISSNs: 1759-8885

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jphs12049-sec-0001" sec-type="section"> <title>Objective</title> <p>The purpose of this study is to compare patient‐reported outcomes (PROs) such as health‐related quality of life, mental disorder and psychological distress among users of time‐release (TR) versus immediate‐release formulations of three commonly prescribed antidepressants in a sample of the US working population.</p> </sec> <sec id="jphs12049-sec-0002" sec-type="section"> <title>Methods</title> <p>Adjusted multiple linear and logistic regression analyses using data from 2004 to 2010 Medical Expenditures Panel Surveys were conducted. The health‐related quality of life was measured based on the Physical Component Summary (PCS‐12) and the Mental Component Summary (MCS‐12) of the SF‐12v2. The mental disorder and the psychological distress were measured by the Patient Health Questionniare‐2 and the Kessler 6 respectively.</p> </sec> <sec id="jphs12049-sec-0003" sec-type="section"> <title>Key findings</title> <p>The utilization of TR formulations was not associated with higher scores in the SF12‐v2, (β = −0.546, <italic>P</italic> = 0.442) and (β = −0.806, <italic>P</italic> = 0.346) for both PCS‐12 and MCS‐12 respectively. The users of TR formulations did not significantly differ in their likelihood of having a score of ≥3 in the Patient Health Questionniare‐2 (OR = 1.048, <italic>P</italic> = 0.677). Furthermore, the utilization of TR formulations was not associated with lower scores in the Kessler 6 Scale (β = 0.073, <italic>P</italic> = 0.846).</p> </sec> <sec id="jphs12049-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Although controlled clinical trials report favourable tolerability profiles for TR formulations, it still remains unclear whether these formulations lead to better PROs in real‐world patient‐care settings.</p> </sec> </abstract>